Search

Your search keyword '"Cozzolongo, R."' showing total 233 results

Search Constraints

Start Over You searched for: Author "Cozzolongo, R." Remove constraint Author: "Cozzolongo, R."
233 results on '"Cozzolongo, R."'

Search Results

1. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept

2. Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid

3. Long-term results from the Italian real-world experience on obeticholic acid treatment in primary biliary cholangitis: The RECAPITULATE study

4. Prediction of response to obeticholic acid in primary biliary cholangitis: Development and validation of the OCA response score (ORS)

5. Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications

6. Real-world experience with obeticholic acid in patients with primary biliary cholangitis

7. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites

10. Long-term albumin administration eases the management of hyponatremia in outpatients with decompensated cirrhosis: data from the ANSWER Trial

11. Predictors of Serious Adverse Event and Non-response in Cirrhotic Patients With Primary Biliary Cholangitis under Obeticholic Acid

13. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

14. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

15. Worldwide prevalence, genotype distribution and management of hepatitis C

16. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis

17. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy

18. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

19. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

20. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

21. Long-term albumin therapy is not futile in patients with cirrhosis and uncomplicated ascites not normalizing on-treatment serum albumin concentration

22. Analysis of resistance and phylogenetic clusters in HCV-2c infected patients within the Italian network Vironet C

23. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen

24. Real-world data on the treatment of primary biliary cholangitis with obeticholic acid in Italy: the CLEO-AIGO OCA cohort

27. DECLINE OF PREVALENCE OF RESISTANCE ASSOCIATED SUBSTITUTIONS TO NS3 AND NS5A INHIBITORS AT DAA- FAILURE IN HEPATITIS C VIRUS IN ITALY OVER THE YEARS 2015 TO 2018

29. Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience

31. Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study

32. L'Italia come modello per l'Europa e per il mondo nelle politiche sanitarie per il trattamento dell'epatite cronica da HCV

33. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience

34. Long-term albumin administration in patients with cirrhosis and uncomplicated ascites: the use of serum albumin concentration for personalizing treatment

35. Long-term use of human albumin for the treatment of ascites in patients with hepatic cirrhosis: the interim analysis of the ANSWER study

36. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

37. The challenge of HCV-retreatment after DAA-failure: Italian real-life from VIRONET-C network

38. Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies

39. The challenge of HCV-retreatment after DAA-failure: real-life experience advocates for caution

40. Multiclass hepatitis C virus resistance to direct acting antivirals in real life interferon-free regimens failures advocates for tailored second-line therapies

41. Long-term albumin administration improves survival in patients with decompensated cirrhosis: final results of the “ANSWER” study

42. Optimization of direct antiviral agent treatment schedule in hepatitis C virus genotype 3 infection: an Italian, multicentetric experience in real-life setting

43. Hepatitis C virus clearance after direct-acting antivirals in cirrhotic patients by stages of liver impairment: the ITAL-C network study

44. Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2° and ribavirin

45. Extended duration of therapy with peginterferon alpha 2b and weight based ribavirin in HCV patients with genotype 3 infection

48. Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B

49. Long-term use of human albumin for the treatment of ascites in patients with hepatic cirrhosis: The interim analysis of the ANSWER study

Catalog

Books, media, physical & digital resources